Fagron NV (FRA:4A5)

Market Cap	1.55B +11.1%
Revenue (ttm)	952.17M +9.2%
Net Income	91.02M +13.0%
EPS	1.24 +12.7%
Shares Out	n/a
PE Ratio	17.06
Forward PE	14.29
Dividend	0.25 (1.13%)
Ex-Dividend Date	May 19, 2025

Volume	n/a
Average Volume	5
Open	21.30
Previous Close	21.30
Day's Range	21.30 - 21.30
52-Week Range	17.74 - 23.30
Beta	n/a
RSI	43.40
Earnings Date	Jul 30, 2026

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for av...

• Industry: Medical, Dental, and Hospital Equipment and Supplies
• Founded: 1990
• Employees: 4,193
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4A5

Financial Performance

In 2025, Fagron NV's revenue was 952.17 million, an increase of 9.20% compared to the previous year's 871.96 million. Earnings were 91.02 million, an increase of 12.99%.